Keppra
Neuralgia, Postherpetic
UCB PharmaPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Neuralgia, Postherpetic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- University of Medicine and Pharmacy at Ho Chi Minh City | Phase 4 | BBB |
Capsaicin Astellas Pharma Europe Ltd. | Phase 4 | BBB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Shirong Tan | Phase 4 | BB |
Gabapentin Enacarbil XenoPort, Inc. | Phase 2 | B |
Tak-583 Takeda | Phase 2/3 | B |
View all 18 →
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →